Fig. 5: In vivo dosing of PROTAC 6 in rats caused the degradation of RIPK2 and a decrease in TNFα levels upon ex vivo L18-MDP challenge.
From: Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
We determined the effect of dosing PROTAC 6 (0.005, 0.05 and 0.5 mg/kg SC) in rats on (a) RIPK2 levels compared to pre-dose levels and (b) TNFα levels following ex vivo L18-MDP challenge compared to the vehicle control group. Combined PK and PD time profiles are shown for 0.05 mg/kg (c) QD and (d) Q3D and (e) 0.15 mg/kg Q3D administered SC. f Effect of dosing PROTAC 6 (0.05 and 0.5 mg/kg QD SC) in rats on RIPK2 levels in colon compared to vehicle control group. Data are shown as mean±s.e.m and n = 4–5/group. P values calculated by ANOVA Dunett test comparing control vs. PROTAC (**P < 0.01, ***P < 0.001).
